Home
-> News & Events -> News -> Pharmaceuticals & Life Sciences -> SJ Berwin Advises BioXell on Licence Agreement
News | Pharmaceuticals & Life Sciences
SJ Berwin Advises BioXell on Licence Agreement
The licensee, one of the world's leading pharmaceutical companies, will obtain exclusive rights to develop BioXell's initial product candidate directed to TREM-1, currently in preclinical development, and other candidates directed to the TREM-1 target. The licensee and BioXell will also collaborate on the further research of other TREM receptors.
The SJ Berwin team was lead by Commerce & Technology partner Andrew Shindler, a member of the firm's cross departmental Pharmaceutical Group. Commenting on the deal, Andrew said: "We were delighted to work with BioXell on this significant licensing agreement. The collaborative approach of both parties ensured a smooth and swift resolution of the complex legal and commercial issues inevitably involved in this type of deal, which we hope will result in significant benefit to future patients".
Meenu Chhabra, BioXell's Executive Director of Business Development said: "We are extremely pleased that our licensee is as excited as we are about the potential of the TREM platform, and believe this collaboration may be beneficial for patients."
SJ Berwin has a very active Pharmaceutical Group advising on a wide range of legal issues from licensing in and out of pharmaceutical products; advising on and drafting R&D and distribution agreements; contentious and non-contentious intellectual property related work, pharmaceutical regulatory law (in particular the application of EU pharmaceutical legislation, and anti-trust and unfair competition); product liability claims, and a wide spectrum of associated corporate and commercial advice relating to the pharmaceutical world.
Notes:
Back to
news
Thursday 26th May 2005
SJ Berwin has announced that it advised BioXell, the Italian biopharmaceutical company on its recently concluded exclusive, worldwide licence agreement for development of TREM (Triggering Receptors Expressed on Myeloid Cells) related therapeutic and diagnostic products, which is the subject of a press release issued by BioXell on 23 May. Under the terms of the agreement, BioXell will receive an up-front payment and, in addition, could receive as much as $150 million in milestone payments, including $55.5 million for the successful development of the first product for the first indication and additional milestone payments for further development of the first candidate and follow-on product candidates in subsequent indications, and has a right to royalties on future product sales upon completion of all required clinical trials and product approvals.The licensee, one of the world's leading pharmaceutical companies, will obtain exclusive rights to develop BioXell's initial product candidate directed to TREM-1, currently in preclinical development, and other candidates directed to the TREM-1 target. The licensee and BioXell will also collaborate on the further research of other TREM receptors.
The SJ Berwin team was lead by Commerce & Technology partner Andrew Shindler, a member of the firm's cross departmental Pharmaceutical Group. Commenting on the deal, Andrew said: "We were delighted to work with BioXell on this significant licensing agreement. The collaborative approach of both parties ensured a smooth and swift resolution of the complex legal and commercial issues inevitably involved in this type of deal, which we hope will result in significant benefit to future patients".
Meenu Chhabra, BioXell's Executive Director of Business Development said: "We are extremely pleased that our licensee is as excited as we are about the potential of the TREM platform, and believe this collaboration may be beneficial for patients."
SJ Berwin has a very active Pharmaceutical Group advising on a wide range of legal issues from licensing in and out of pharmaceutical products; advising on and drafting R&D and distribution agreements; contentious and non-contentious intellectual property related work, pharmaceutical regulatory law (in particular the application of EU pharmaceutical legislation, and anti-trust and unfair competition); product liability claims, and a wide spectrum of associated corporate and commercial advice relating to the pharmaceutical world.
Notes:
- SJ Berwin is a full-service international legal practice with more than 470 lawyers across its offices in London, Brussels, Frankfurt, Berlin, Munich, Madrid and Paris.
- SJ Berwin's Pharmaceutical Group is a specialist team of cross-departmental lawyers with extensive experience and expertise in advising pharmaceutical, healthcare and biotech firms across the full spectrum of legal and regulatory issues relevant to the sector.
About BioXell - Spun-out from Roche in January of 2002, BioXell is a private biopharmaceutical company focusing on the discovery and development of new treatments for urological disorders that represent large, currently underserved markets. Through its proprietary technology platform based on Vitamin D3 analogues, BioXell has identified a number of promising lead development programmes. Its pipeline includes BXL 628 for benign prostatic hyperplasia and overactive bladder, currently in Phase II of clinical development, as well as compounds to treat other major urological indications such as interstitial cystitis and nonbacterial chronic prostatitis. In order to further exploit its Vitamin D3 platform, BioXell is collaborating with ProStrakan to develop drug candidates to treat osteoporosis and secondary hyperparathyroidism. Furthermore, based on its unique understanding of the inflammatory process and knowledge of GPCRs and TREM receptor biology, BioXell is also committed to a number of cutting-edge research projects to develop new drugs for chronic inflammatory diseases in collaboration with external partners. To date, BioXell has raised a total of over €70m through world-class specialised healthcare VC investors including MPM Capital, Index Ventures, BB BIOTECH, AlpInvest Partners and Life Sciences Partners as well as government funding. BioXell currently employs 60 people and has sites in Milan, Italy and Nutley, NJ, USA.
- More information on BioXell can be found on: www.bioxell.com
Back to
news
site map | privacy statement | legal notices | ©2008 SJ Berwin
